Deccan Healthcar (542248)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at a discount to book value: P/B 0.87 with book value ₹40.97 versus price ₹35.53
• Piotroski F-score of 6/9 suggests moderately sound financial health
• P/E of 14.74 is not excessive for a profitable small-cap
• Latest quarter turned a profit: ₹17 Cr sales and ₹1 Cr net profit

Concerns

• Sales fell 14.88%, showing a shrinking top line
• ROE of 2.22% and ROCE of 1.65% indicate weak returns on capital and likely weak moat
• Profit growth of 614.29% is misleading because it comes from a very low base
• No dividend, and promoter holding and debt/equity data are undisclosed, limiting transparency

AI Analysis

At ₹35.53, Deccan Healthcar trades below its book value of ₹40.97, giving me a P/B of 0.87. A bargain price, yes, but as Graham warned, a low price can be a trap if the business itself is mediocre. The numbers here tell a sober story: ROE is just 2.22% and ROCE only 1.65%. That means every rupee of capital employed earns very little. This is not a franchise with pricing power or a durable moat; it is a small healthcare service provider struggling to grow, with sales down 14.88%. The 614.29% profit growth looks eye-catching, but it is from a tiny base and cannot be taken at face value. In the latest quarter, sales were ₹17 Cr and net profit only ₹1 Cr—thin margins. So the earnings jump is not evidence of a great business. The P/E of 14.74 is not demanding, but a low multiple on weak earnings is not automatically cheap. There is some comfort: the Piotroski F-score of 6 suggests the balance sheet is not deteriorating badly, and no dividend means I get no income while waiting. Also, without promoter holding data or debt-to-equity details, I cannot fully judge management's skin in the game or leverage risk. The stock has moved from ₹6.65 to ₹35.53, so Mr. Market has already re-rated it. I would need to see actual improvement in return on capital and a halt to the sales decline before I call this a true value investment. For now, it remains a possible asset play, but only for those who can verify the book value and wait patiently.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer